<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172197</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002136-15</org_study_id>
    <secondary_id>2008-002136-15</secondary_id>
    <secondary_id>2008 AN02</secondary_id>
    <secondary_id>08/S1402/30</secondary_id>
    <secondary_id>24891/0009/001-0001</secondary_id>
    <nct_id>NCT01172197</nct_id>
  </id_info>
  <brief_title>Comparison of Levobupivacaine and Ropivacaine for Femoral Neural Block</brief_title>
  <official_title>A Randomised Single Blind Study Comparing the Molar Median Effective Dose of Levobupivacaine and Molar Median Effective Dose of Ropivacaine When Administered as a Femoral Perineural Infusion for Pain Relief After Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Tayside</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anaesthetic management of patients undergoing total knee replacement is still not&#xD;
      standardised. Epidural analgesia is common, but is associated with bilateral lower limb motor&#xD;
      block and limited mobilisation. Spinal anaesthesia with intrathecal morphine provides good&#xD;
      pain relief, but only for 12 to 16 hours, and is often associated with nausea and vomiting.&#xD;
      Combined single injection femoral / sciatic blocks give good pain relief, but for a variable&#xD;
      length of time (between 12 and 24 hours).&#xD;
&#xD;
      In contrast, continuous femoral perineural infusion of local anaesthetic provides very good&#xD;
      pain relief for several days. Pain relief is maintained by a constant infusion of local&#xD;
      anaesthetic using an elastomeric ball. The investigators overriding aim is to develop a local&#xD;
      anaesthetic regimen which offers complete pain relief for at least 48 hours, yet allows full&#xD;
      mobilisation within 24 hours Given that ropivacaine may offer a more advantageous&#xD;
      pharmacological profile (less lipid solubility) compared to levobupivacaine, the&#xD;
      investigators feel it is pertinent to investigate the capacity of ropivacaine to prevent pain&#xD;
      relief after surgery. Thus, the investigators aim in this study is to compare the median&#xD;
      effective dose of levobupivacaine with the of ropivacaine for preventive pain relief after&#xD;
      total knee replacement. Further, calculation of the equipotent median effective dose's of&#xD;
      each local anaesthetic allied to objective measurement of quadriceps motor block using an&#xD;
      electromyogram will allow us to determine the sensory - motor split of each local&#xD;
      anaesthetic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective The primary aim of this study is to measure the molar of levobupivacaine&#xD;
      and the molar median effective dose of ropivacaine when administered as a femoral perineural&#xD;
      infusion to prevent pain 30 hours after total knee replacement Secondary objectives&#xD;
&#xD;
      To assess the:&#xD;
&#xD;
      Degree of postoperative pain, need for rescue analgesia,side effect profile of both groups,&#xD;
      self-efficacy, expectancy, quality of life / health economics Type of study: Prospective&#xD;
      single blind randomised controlled trial Planned number of subjects: 48 Study duration: 24&#xD;
      months Randomisation procedures Following informed consent, participants will be randomised&#xD;
      into two groups. All preparations for study will be coded so that participants have an equal&#xD;
      chance of receiving one of the two local anesthetics. Randomisation will be carried out by&#xD;
      computer program, and codes kept in pharmacy in a sealed envelope.&#xD;
&#xD;
      Protocol for patient management Preoperative - Anaesthetic room Antibiotics: augmentin 1.2&#xD;
      grams Sedation with Target Controlled Infusion of propofol at plasma level of 0.5 micrograms&#xD;
      per millilitre (μg.ml-1) Spinal anaesthesia with 3.2 ml hypobaric &quot;plain&quot; bupivacaine 0.5%&#xD;
      and intrathecal morphine 0.1 mg All regional nerve blocks performed under ultrasound control&#xD;
      Femoral block: 15 ml 0.3% levobupivacaine or ropivacaineFemoral perineural catheter inserted&#xD;
      by Anaesthetist 5cm in a cranial direction Sciatic block: single injection 12 ml 0.5%&#xD;
      levobupivacaine or ropivacaine Obturator block: single injection 6 ml 0.5% levobupivacaine or&#xD;
      ropivacaine&#xD;
&#xD;
      Postoperative 8 hour anaesthetic observation&#xD;
&#xD;
      Determine median effective dose of levobupivacaine and ropivacaine for anaesthesia 8 hours&#xD;
      after insertion of spinal needle, resolution of spinal anaesthesia confirmed and verbal&#xD;
      rating pain score of knee bending recorded. Clinical measurement and subsequent patient&#xD;
      dosing is as follows:&#xD;
&#xD;
        1. &quot;Anaesthetic success&quot;: verbal rating pain score = 0: Next patient receives 10 microMolar&#xD;
           (μM) less of levobupivacaine or 10μM ropivacaine.&#xD;
&#xD;
        2. &quot;Anaesthetic failure&quot;: verbal rating pain score ≥ 1. Resolved by rescue analgesia of&#xD;
           15ml, 150μM levobupivacaine (5.8ml, 0.75%) or 15ml, 150μM ropivacaine (6.2ml,&#xD;
           0.75%).Next patient receives 10μM more of levobupivacaine or 10μM ropivacaine.&#xD;
&#xD;
        3. Technical failure: verbal rating pain score ≥ 1 Not resolved by rescue analgesia of&#xD;
           15ml, 150μM levobupivacaine (5.8ml, 0.75%) or 15ml, 150μM ropivacaine (6.2ml, 0.75%.Next&#xD;
           patient receives same mass levobupivacaine or ropivacaine.&#xD;
&#xD;
      After the 8 hour assessment, all patients (excluding technical failures but including&#xD;
      &quot;anaesthetic failures&quot;) will start a femoral perineural infusion with levobupivacaine or&#xD;
      ropivacaine at a rate of 10ml h-1 and concentration of 1(microMolar per millilitre) μM.ml-1&#xD;
      (400μM in 400ml elastomeric ball) for 48 hours.Patients classed as &quot;technical failure&quot; will&#xD;
      have a femoral perineural catheter reinserted.&#xD;
&#xD;
      Postoperative 30 hour (±2hour) anaesthetic observation&#xD;
&#xD;
      The postoperative 30 hour anaesthetic observation will only be performed on the &quot;anaesthetic&#xD;
      successes&quot; from the 8 hour observation. The median effective dose of levobupivacaine and&#xD;
      ropivacaine for analgesia will be determined by choosing an end point of verbal rating pain&#xD;
      score 0 at 30h after the start of spinal anaesthesia. Patients will divide into three groups:&#xD;
&#xD;
        1. &quot;Successful pain relief&quot; verbal rating pain score = 0 Next patient receives 10μM less of&#xD;
           levobupivacaine or 10μM ropivacaine.&#xD;
&#xD;
        2. &quot;Unsuccessful pain relief&quot; verbal rating pain score ≥ 1 resolved by rescue analgesia of&#xD;
           15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or 15ml, 50μM ropivacaine (7.7ml,&#xD;
           0.20% + saline).Next patient receives 10μM more of levobupivacaine or 10μM ropivacaine.&#xD;
&#xD;
        3. Technical failure: verbal rating pain score ≥ 1. Not resolved by rescue analgesia of&#xD;
           15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or ml, 50μM ropivacaine (7.7ml, 0.20%&#xD;
           + saline).&#xD;
&#xD;
      Rescue analgesia Rescue will be standardised: 15ml, 50μM levobupivacaine (5.8ml, 0.25% +&#xD;
      saline) or 15ml, 50μM ropivacaine (7.7ml, 0.20% + saline). The number of rescue&#xD;
      administrations will be counted.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated prior to its planned completion as anticipated by the protocol).&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>30 hours</time_frame>
    <description>Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pain</condition>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local anaesthetic bolus and infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local anaesthetic bolus and infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>Femoral bolus 150μM followed by femoral infusion 400μM</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Chirocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Bolus and infusion</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients &gt;18 years of age and non pregnant presenting for elective knee&#xD;
             replacement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of cardiac failure (3rd heart sound, lung crepitations)&#xD;
&#xD;
          -  Type I and type II diabetes&#xD;
&#xD;
          -  Abnormal cardiac arrhythmias&#xD;
&#xD;
          -  Hypovolaemia&#xD;
&#xD;
          -  Presence of seizures,&#xD;
&#xD;
          -  Dementia,&#xD;
&#xD;
          -  Depression&#xD;
&#xD;
          -  Encephalopathy,&#xD;
&#xD;
          -  Terminal illness with a life expectancy &lt; 3 months&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme A McLeod, MD FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Tayside</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>local anesthetic</keyword>
  <keyword>levobupivacaine</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>femoral perineural block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited on ward 24h before procedure. Patient information sheet sent to patients 3 weeks before operation</recruitment_details>
      <pre_assignment_details>Nil to report</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine</title>
          <description>Local anaesthetic bolus and infusion&#xD;
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="P2">
          <title>Levobupivacaine</title>
          <description>Local anaesthetic bolus and infusion&#xD;
Ropivacaine: Bolus and infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine</title>
          <description>Local anaesthetic bolus and infusion&#xD;
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="B2">
          <title>Levobupivacaine</title>
          <description>Local anaesthetic bolus and infusion&#xD;
Ropivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="53" upper_limit="70"/>
                    <measurement group_id="B2" value="64" lower_limit="56" upper_limit="72"/>
                    <measurement group_id="B3" value="62" lower_limit="53" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion</description>
        <time_frame>30 hours</time_frame>
        <population>Knee replacement. All obtained pain relief defined as pain score = 0 on a verbal pain rating scale</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Local anaesthetic bolus and infusion&#xD;
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
          </group>
          <group group_id="O2">
            <title>Levobupivacaine</title>
            <description>Local anaesthetic bolus and infusion&#xD;
Ropivacaine: Bolus and infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion</description>
          <population>Knee replacement. All obtained pain relief defined as pain score = 0 on a verbal pain rating scale</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30h</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine</title>
          <description>Local anaesthetic bolus and infusion&#xD;
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="E2">
          <title>Levobupivacaine</title>
          <description>Local anaesthetic bolus and infusion&#xD;
Ropivacaine: Bolus and infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr G McLeod</name_or_title>
      <organization>NHS Tayside</organization>
      <phone>+44 1382 7974440848</phone>
      <email>g.a.mcleod@dundee.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

